



Product Specification Sheet

Product Name: R848**Catalog Number:** C7848**Technical information:**Chemical Formula: $C_{17}H_{22}N_4O_2$

CAS #: 144875-48-9

Molecular Weight: 314.38

Purity: > 98%


Appearance: White solid

Solubility: Soluble in DMSO up to 50 mM

Chemical Name: 1-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol

Storage: For longer shelf life, store solid powder or DMSO solution at -20°C desiccated.

Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.



- Handling:**
- To make 10 mM stock solution, add 0.318mL of DMSO for each mg of R848.
 - For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

Biological Activity: R848 (Resiquimod) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF- α , IL-6 and IFN- α . R848 is being developed for HCV infection treatment [1], as vaccine adjuvants [2], and as combined cancer immunotherapy agent [3]

- Reference:**
1. Rockros PJ, et al. Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J. Hepatol. 2007; 47(2): 174-182 Pubmed ID: doi.org/10.1016/j.jhep.2007.02.025
 2. Risini D, et al. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 2005; 23(45): 5263-5270 Pubmed ID: https://doi.org/10.1016/j.vaccine.2005.06.024
 3. Block MS, et al. A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1. Melanoma Res. 2019; 29(4): 420-427 Pubmed ID: 30520800

To reorder: <http://www.cellagentech.com/R848/>For Technical Support: technical@cellagentech.com

Chemicals are sold for research use only, not for clinical or diagnostic use.